Mechanisms of amyloidosis and the proteins involved;Mecanismes de l'amylose et proteines impliquees

Revue de Medecine Interne

Volumn 21, Issue 1, 2000, Pages 35-49

  Lebrazi, H ^a   Hachulla, E ^b   Saile R ^a  

^a FACULTÉ DES SCIENCES BEN M SIK   (Morocco)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Amyloidosis; Classification; Physiopathology

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID P COMPONENT; APOLIPOPROTEIN E; BETA 2 MICROGLOBULIN; GLYCOSAMINOGLYCAN; SERUM AMYLOID A;

ALZHEIMER DISEASE; AMYLOIDOSIS; DISEASE CLASSIFICATION; HUMAN; IMMUNOHISTOCHEMISTRY; PATHOPHYSIOLOGY; PROTEIN ANALYSIS; REVIEW; SENILE PLAQUE;

AMYLOID BETA-PROTEIN; AMYLOIDOSIS; HUMANS; SENILE PLAQUES; SERUM AMYLOID A PROTEIN;

EID: 0033972329     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0248-8663(00)87227-6     Document Type: Article

References (117)

1. Glenner GG. Amyloid deposits and amyloidosis - the β-fibrilloses I. N Engl J Med 1980 ; 302 : 1283-92.
2. Glenner GG. The basis of the staining of amyloid fibers: Their physicochemical nature and the mechanisms of their dye-substrate interaction. Prog Histochem Cytochem 1981 ; 13 : 1-37
3. Turnell W, Sarra R, Glover ID, Baum JO, Caspi D, Baltz ML, et al. Secondary structure prediction of human SAA1: Presumptive identification of calcium and lipid binding sites. Mol Biol Med 1986 ; 3 : 387-407.
4. Turnell W, Sarra R, Baum JO, Caspi D, Baltz ML, Pepys MB. X-ray scattering and diffraction by wet gels of AA amyloid fibrils. Mol Biol Med 1986 ; 3 : 409-24.
5. Skogen B, Natvig JB. Degradation of amyloid proteins by different serine proteases. Scand J Immunol 1981 ; 14 : 389-96.
6. Glenner GG, Terry W, Harada M, Isersky C, Page D. Amyloid fibril proteins: Proof of homology with immunoglobulin light chains by sequence analyses. Science 1971 ; 172 : 1150-1.
7. Glenner GG, Ein D, Eanes ED, Bladen HA, Terry W, Page DL. Creation of "amyloid" fibrils from Bences Jones proteins in vitro. Science 1971 ; 174 : 712-4.
8. Glenner GG, Terry WD, Isersky C. Amyloidosis: Its nature and pathogenesis. Semin Hematol 1973 ; 10 : 65-86.
9. Cathcart ES, Ritchie RF, Cohen AS, Brandt K. Immunoglobulins and amyloidosis: An immunologic study of sixty-two patients with biopsy-proved disease. Am J Med 1972 ; 52 : 93-101.
10. Solomon A, Frangione B, Franklin EC. Bences-Jonces proteins and light chains of immunoglobulins: Preferential association of the lambda VI subgroup of human light chains with amyloidosis AL (lambda). J Clin Invest 1982 ; 70 : 453-60.
11. Levin M, Franklin EC, Frangione B, Pras M. The amino acid sequence of a major non immunoglobulin component of some amyloid fibrils. J Clin Invest 1972 ; 51 : 2773-6.
12. Rosenthal CJ, Franklin EC, Frangione B, Greenspan J. Isolation and partial characterization of SAA - An amyloid-related protein from human serum. J Immunol 1976 ; 116 : 1415-8.
13. Levin M, Pras M, Franklin EC. Immunologic studies of the major nonimmunoglobulin protein of amyloid. Identification and partial characterization of a related serum component. J Exp Med 1973 ; 138 : 373-80.
14. Benditt EP, Hoffman JS, Eriksen N, Parmelee DC, Walsh KA. SAA, an apoprotein of HDL: Its structure and function. Ann N Y Acad Sci 1982 ; 389 : 183-9.
15. Coetzee GA, Strachan AF, Van der Westhuyzen DR, Hoppe HC, Jeenah MS, de Beer FC. Serum amyloid A-containing human high density lipoprotein 3. Density, size, and apolipoprotein composition. J Biol Chem 1986 ; 21 : 9644-51.
16. de Beer FC, Mallga RK, Fagan EA, Lanham JG, Hugues GRV, Pepys MB. Serum amyloid A protein concentration in inflammatory diseases and its relationship to the incidence of reactive systemic amyloidosis. Lancet 1982 ; ii : 231-4.
17. Saïle R, Fruchart JC. L'apolipoprotéine sérique amyloïde A (apo SAA): Implication dans l'inflammation et dans les modifications des lipoprotéines. Ann Biol Clin 1990 ; 48 : 77-85.
18. Saïle R, Delpierre C, Puchois P, Hocke G, Cachera C, Gesquière JC, et al. Enzyme linked immunosorbent assay for serum amyloid A apolipoprotein with use of specific antibodies against synthetic peptides. Clin Chem 1988 ; 34 : 1767-71.
19. Saïle R, Hocke G, Tartar A, Fruchart JC, Steinmetz A. Antipeptide antibodies discriminate between different SAA proteins in human plasma. Biochim Biophys Acta 1989 ; 992 : 407-8.
20. Hachem H, Saïle R, Favre G, Bosco R, Raynal G, Fruchart JC, et al. A sensitive immunochemiluminescence assay for serum amyloid A. Clin Biochem 1991 ; 24 : 143-7.
21. Patel H, Bramall J, Waters H, de Beer FC, Woo P. Expression of recombinant human serum amyloid A in mammalian cells and demonstration of the region necessary for high-density lipoprotein binding and amyloid fibril formation by site-directed mutagenesis. Biochem J 1996 ; 318 : 1041-9.
22. Kabbaj O, Saïle R, Ghalim N, Parra HJ, Puchois P, Fruchart JC, et al. Analyse quantitative des apolipoprotéines et des particules lipoprotéiniques chez les traumatisés crâniens. Ann Biol Clin 1989 ; 47 : 35-40.
23. Steinmetz A, Hocke G, Saïle R, Puchois P, Fruchart JC. Influence of serum amyloid A on cholesterol esterification in human plasma. Biochim Biophys Acta 1989 ; 1006 : 173-8.
24. Saïle R, Kabbaj O, Visvikis S, Steinmetz J, Steinmetz A, Ferard G, et al. Variations in apolipoproteins serum amyloid A, A-I, A-II and C-III in severely head injured patients. J Clin Chem Clin Biochem 1990 ; 28 : 519-25.
25. Hosoai H, Webb NR, Glick JM, Tietge UJ, Purdom MS, de Beer FC, et al. Expression of serum amyloid A protein in the absence of the acute phase response does not reduce HDL cholesterol or apoA-I levels in human apoA-I transgenic mice. J Lipid Res 1999 ; 40 : 648-53.
26. Le Loet X, Ducastelle T, Deshayes P. Amylose: Acquisitions récentes. Ann Méd Interne 1982 ; 133 : 152-9.
27. Jacquot C, D'Auzac C, Loirat P, Bariety J. Aggravation foudroyante d'amylose rénale après chirurgie. Trois observations. Nouv Presse Méd 1981 ; 10 : 3389-95.
28. Migita K, Eguchi K, Tsukada T, Kawabe Y, Takashima H, Mine M, et al. Increased circulation serum amyloid A protein derivatives in rheumatoid arthritis patients with secondary amyloidosis. Lab Invest 1996 ; 75 : 371-5.
29. Maury CPJ, Teppo AM. Mechanism of reduced amyloid-A-degrading activity in serum of patients with secondary amyloidosis. Lancet 1982 ; ii : 234-7.
30. Bausserman LL, Herbert PN, McAdam KP. Heterogeneity of serum amyloid A proteins. J Exp Med 1980 ; 152 : 641-56.
31. Shiroo M, Kawahara E, Nakanishi I, Migita S. Specific deposition of serum amyloid A protein 2 in the mouse. Scand J Immunol 1987 ; 26 : 709-16.
32. Ham D, Caouras V, Radzioch D, Gervais F. Degradation of amyloid A precursor protein SAA by macrophage cell lines obtained from amyloid resistant and susceptible strains of mice. Scand J Immunol 1997 ; 45 : 354-60.
33. Sipe JD, Vogel SN, Sztein MB, Skinner M, Cohen AS. The role of interleukin 1 in acute phase serum amyloid A (SAA) and serum amyloid P (SAP) biosynthetis. Ann N Y Acad Sci 1982 ; 389 : 137-49.
34. Moshage HJ, Roelofs HMJ, Van Pelt JF, Hazenberg BPC, Van Leeuwen MA, Limburg PC, et al. The effect of interleukin-1, interleukin-6 and its interelationship on the synthetis of serum amyloid A and C-reactive protein in primary cultures of adult human hepatocytes. Biochem Biophys Res Commun 1988 ; 155 : 112-7.
35. Xu L, Badolato R, Murphy WJ, Longo DL, Anver M, Hale S, et al. A novel biologic function of serum amyloid A. Induction of lymphocyte migration and adhesion. J Immunol 1995 ; 155 : 1184-90.
36. Aldo-Benson MA, Benson MD. SAA suppression of immune response in vitro: Evidence for an effect on T cell-macrophage interaction. J Immunol 1982 ; 128 : 2390-2.
37. Liang JS, Schreiber BM, Salmona M, Phillip G, Gonnerman WA, de Beer FC, et al. Amino terminal region of acute phase, but not constitutive, serum amyloid A (apoSAA) specifically binds and transports cholesterol into aortic smooth muscle and HepG2 cells. J Lipid Res 1996 ; 37 : 2109-16.
38. Benson MD, Wallace MR. Amyloidosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Basis of Inherited Disease, Ed 6, vol 2. New York: McGram-Hill; 1989. p. 2439.
39. Pras M, Prelli F, Franklin EL, Frangione B. Primary structure of an amyloid prealbumin variant in familial polyneuropathy of Jewish origin. Proc Natl Acad Sci 1983 ; 80 : 539-42.
40. Tawara S, Nakazato M, Kangawa K, Matsuo H, Araki S. Identification of amyloid prealbumin variant in familial amyloidotic polyneuropathy (Japanese type). Biochem Biophys Res Commun 1983 ; 116 : 880-8.
41. Dwulet FE, Benson MD. Primary structure of an amyloid prealbumin and its plasma precursor in a heredofamilial polyneuropathy of Swedish origin. Proc Natl Acad Sci 1984 ; 81 : 694-8.
42. Saraiva MJM, Birken S, Costa PP, Goodman DS. Amyloid fibril protein in familial amyloid polyneuropathy, Portuguese type. Definition of molecular abnormality in transthyretin (prealbumin). J Clin Invest 1984 ; 74 : 104-19.
43. Wallace MR, Dwulet FE, Conneally PM, Benson MD. Biochemical and molecular genetic characterization of a new variant prealbumin associated with hereditary amyloidosis. J Clin Invest 1986 ; 78 : 6-12.
44. Dwulet FE, Benson MD. Characterization of transthyretin (prealbumin) variant associated with familial amyloid polyneuropathy type II (Indiana/Swiss). J Clin Invest 1986 ; 78 : 880-6.
45. Yoshioka K, Sasaki H, Yoshioka N, Furuya H, Harada T, Kito S, et al. Structure of the mutant prealbumin gene responsible for familial amyloidotic polyneuropathy. Mol Biol Med 1986 ; 3 : 319-28.
46. Kelly JW, Colon W, Lai Z, Lashuel HA, McCulloch J, McCutchen SL, et al. Transtyretin quaternary ane tertiary structural changes facilitate misassembly into amyloid. Adv Protein Chem 1997 ; 50 : 161-81.
47. Corneall GG, Sletten K, Olofsson BO, Johansson B, Westermark P. Prealbumin: Its association with amyloid. J Clin Pathol 1987 ; 40 : 226-31.
48. Gustavsson A, Jahr H, Tobiassen R, Jacobson DR, Sletten K, Westermark P. Amyloid fibril composition and transthyretin gene structure in senile systemic amyloidosis. Lab Invest 1995 ; 73 : 703-8.
49. Glenner GG, Wong CW. Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984 ; 120 : 885-90.
50. Glenner GG, Wong CW. Alzheimer's disease and Down's syndrome: Sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun 1984 ; 122 : 1131-5.
51. Masters CL, Simms G, Weinman NA, Beyreuther K, Multhaup G, McDonald LA. Amyloid plaque core protein in Alzheimer disease and down syndrome. Proc Natl Acad Sci USA 1985 ; 82 : 4245-9.
52. Kang J, Lemaire H-G, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987 ; 325 : 733-6.
53. Goldgaber D, Lerman MI, McBride OW, Saffiotti U, Gajdusek DC. Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease. Science 1987 ; 234 : 877-80.
54. Tanzi RE, St George-Hyslop PH, Haines JL, Polinsky RJ, Nee L, Foncin JF, et al. The genetic defect in familial Alzheimer's disease is not tightly linked to the amyloid β-protein gene. Nature 1987 ; 329 : 156-7.
55. Selkoe DJ, Bell DS, Podlisny MB, Price DL, Cork LC. Conservation of brain amyloid proteins in aged mammals and humans with Alzheimer's disease. Science 1987 ; 235 : 873-6.
56. St George-Hyslop PH, Tanzi RE, Polinsky RJ, Haines JL, Nee L, Watkins PC, et al. The genetic defect causing familial Alzheimer's disease maps on chromosome 21. Science 1987 ; 235 : 885-90.
57. Verbbek MM, Ruiter DJ, de Maal RM. The role of amyloid in the pathogenesis of Alzheimer's disease. Biol Chem 1997 ; 378 : 937-50.
58. Pike CJ, Burdick D, Walencewicz AJ, Glabe CG, Cotman CW. Neurodegeneration induced by β-amyloid peptides in vitro: The role of peptide assembly state. J Neurosci 1993 ; 13 : 1676-87.
59. Weldon DT, Maggio JE, Mantyh PW. New insights into the neuropathology and cell biology of Alzheimer's disease. Geriatrics 1997 ; 52 : S13-6.
60. Ponte P, Gonzalez-DeWhitt P, Miller J, Hsu D, Greenberg B. A new A4 amyloid mRNA contains a domain homologous to serine proteinase inhibitors. Nature (London) 1988 ; 331 : 525-7.
61. 1-antichymotrypsin in the brain amyloid deposits of Alzeimer's disease. Cell 1988 ; 52 : 487-501.
62. Crowther RA, Wischik CM. Image reconstruction of the Alzheimer paired helical filament. Embo J 1985 ; 4 : 3661-5.
63. Wischik CM, Crowther RA, Stewart M, Roth M. Subunit structure of paired helical filaments in Alzeimer's disease. J Cell Biol 1985 ; 100 : 1905-12.
64. Morita T, Suzuki M, Kamimura A, Hirasawa Y. Amyloidosis of a possible new type in patients receiving long-term hemodialysis. Arch Pathol Lab Med 1985 ; 109 : 1029-32.
65. 2-microglobulin. Biochem Biophys Res Commun 1985 ; 129 : 701-6.
66. 2-microglobulin. Biochemistry 1973 ; 12 : 4811-21.
67. 2-microglobulin gene. Primary structure and definition of the transcriptional unit. J Immunol 1987 ; 139 : 3132-8.
68. 2-microglobulin. Biochem Biophys Res Commun 1985 ; 131 : 1063-8.
69. Linke RP, Hampl H, Lobeck H, Ritz E, Bommer J, Waldherr R, et al. Lysine-specific cleavage of β2M in amyloid deposits associated with hemodialysis. Kidney Int 1989 ; 36 : 675-81.
70. Kleinman KS, Coburn JW. Amyloid syndromes associated with hemodialysis. Kidney Int 1989 ; 35 : 567-75.
71. Ballardie FW, Kerr DNS, Tennent G, Pepys MB. Haemodialysis versus CAPD: Equal predisposition to amyloidosis? Lancet 1986 ; i : 795-6.
72. Argilés A, Mourad G, Axelrud-Cavadore C, Watrin A, Mion C, Cavadore JC. High-molecular-mass proteins in haemodialysis-associated amyloidosis. Clin Sci 1989 ; 76 : 547-52.
73. Ogawa H, Saito A, Hirabayashi N, Hara K. Amyloid deposition in systemic organs in long-term hemodialysis patients. Clin Nephrol 1987 ; 28 : 199-204.
74. Bitter T, Muir H. Mucopolysaccharides of whole human spleens in generalized amyloidosis. J Clin Invest 1966 ; 45 : 963-75.
75. Snow AD, Willmer J, Kisilevsky R. Sulfated glycosaminoglycans: A common constituent of all amyloids? Lab Invest 1987 ; 56 : 120-3.
76. Pennock CA. Association of acid mucopolysaccharides with isolated amyloid fibrils. Nature 1968 ; 217 : 753-4.
77. Snow AD, Kisilevsky R. An intimate ultrastructural association between sulphated proteoglycans and AA amyloid fibrils. Lab Invest 1987 ; 56 : 75A.
78. Snow AD, Kisilevsky R. Temporal relationship between glycosaminoglycan accumulation and amyloid deposition during experimental amyloidosis: A histochemical study. Lab Invest 1985 ; 53 : 37-44.
79. Ancsin JB, Kisilevsky R. The heparin/heparan sulfate-binding site on apo-serum amyloid A. Implications for the therapeutic intervention of amyloidosis. J Biol Chem 1999 ; 274 : 7172-81.
80. Castillo GM, Lukito W, Wight TN, Snow AD. The sulfate moieties of glycosaminoglycans are critical for the enhancement of beta-amyloid protein fibril formation. J Neurochem 1999 ; 72 : 1681-7.
81. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen G, et al. Apolipoprotein E: High-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993 ; 90 : 177-81.
82. Chartier-Harlin MC, Parfitt M, Legrain S, Pérez-Tur J, Brousseau T, Evans A, et al. Apolipoprotein E, E4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer's disease: Analysis of the 19q13.2 chromosomal region. Hum Mol Genet 1994 ; 3 : 569-74.
83. Russo C, Angelini G, Dapino D, Piccini A, Piombo G, Schettini G, et al. Opposite role of apolipoprotein E in normal brains and in Alzheimer disease. Proc Natl Acad Sci USA 1998 ; 95 : 15598-602.
84. Castano EM, Prelli F, Pras M, Frangione B. Apolipoprotein E carboxyl-terminal fragments are complexed to amyloids A and L. Implications for amyloidogenesis and Alzheimer's disease. J Biol Chem 1995 ; 270 : 17610-5.
85. Gallo G, Wisniewski T, Choi-Miura NH, Ghiso J, Frangione B. Potential role of apolipoprotein-E in fibrillogenesis. Am J Pathol 1994 ; 145 : 526-30.
86. Weisgraber KH, Innerarity TL, Mahley RW. Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to Cysteine-Arginine interchange at a single site. J Biol Chem 1982 ; 257 : 2518-21.
87. Zarow C, Zaias B, Lyness SA, Chui H. Cerebral amyloid angiopathy in Alzheimer disease associated with apolipoprotein E4 and cortical neuron loss. Alzheimer Dis Assoc Disord 1999 ; 13 : 1-8.
88. Pepys MB, Baltz ML, de Beer FC, Dyck RF, Holford S, Breathnach SM, et al. Biology of serum amyloid P component. Ann N Y Acad Sci 1982 ; 389 : 286-97.
89. Pepys MB, Baltz ML. Acute phase proteins with special reference to C-reactive protein and related proteins (pentraxins) and serum amyloid A protein. Adv Immunol 1983 ; 34 : 141-212.
90. Rowe IF, Jensson O, Lewis PD, Candy J, Tennent GA, Pepys MB. Immunohistochemical demonstration of amyloid P component in cerebrovascular amyloidosis. Neuropathol Appl Neurobiol 1984 ; 10 : 53-61.
91. Prelli F, Pras M, Frangione B. The primary structure of human tissue amyloid P component from a patient with primary idiopathie amyloidosis. J Biol Chem 1985 ; 260 : 12895-8.
92. Thompson AR, Enfield DL. Human plasma P component: Isolation and characterization. Biochemistry 1978 ; 17 : 4304-11.
93. Pepys MB, Dyck RF, de Beer FC, Skinner M, Cohen AS. Binding of serum amyloid P-component (SAP) by amyloid fibrils. Clin Exp Immunol 1979 ; 38 : 284-93.
94. Hind CRK, Collins PM, Renn D, Cook RB, Caspi D, Baltz ML, et al. Binding specificity of serum amyloid P component for the pyruvate acetal of galactose. J Exp Med 1984 ; 59 : 1058-69.
95. 131I-serum amyloid P component. Arthritis Rheum 1987 ; 30 : 1303-6.
96. Pepys MB, Rademacher TW, Amatayakul-Chantler S, Williams P, Noble GE, Hutchinson WL, et al. Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure. Proc Natl Acad Sci USA 1994 ; 91 : 5602-6.
97. Pepys MB, Dash AC, Fletcher TC, Richardson N, Munn EA, Feinstein A. Analogues in other mammals and in fish of human plasma proteins, C-reactive protein and amyloid P-component. Nature (London) 1978 ; 273 : 168-70.
98. Pepys MB, Butler PJG. Serum amyloid P component is the major calcium-dependent specific DNA binding protein of the serum. Biochem Biophys Res Commun 1987 ; 148 : 308-13.
99. Moon EA, MacKinnon AM, Barter PJ. Appearance of serum amyloid protein in high-density lipoproteins of rabbits subjected to relatively mild stimuli. Biochim Biophys Acta 1984 ; 796 : 354-8.
100. Li XA, Hatanaka K, Ishibashi-Ueda H, Yutani C, Yamamoto A. Characterization of serum amyloid P component from human aortic atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1995 ; 15 : 252-7.
101. Garcia de Frutos P, Dahlback B. Interaction between serum amyloid P component and C4b-binding protein associated with inhibition of factor I-mediated C4b degradation. J Immunol 1994 ; 152 : 2430-7.
102. Sorensen IJ, Andersen O, Nielsen EH, Svehag SE. Multiple isoforms of the human pentraxin serum amyloid P component. Int Arch Allergy Immunol 1995 ; 106 : 25-31.
103. Pepys MB, Baltz M, Gomer K, Davies AJS, Doenhoff M. Serum amyloid P-component is an acute phase reactant in the mouse. Nature 1979 ; 278 : 259-62.
104. Baltz ML, Dyck RF, Pepys MB. Amyloid P-component in mice injected with casein identification in amyloid deposits and in the cytoplasm of hepatocytes. Immunology 1980 ; 41 : 59-66.
105. Pepys MB, Dash AC, Markham RE, Thomas HC, Williams BD, Petrie A. Comparative clinical study of protein SAP (amyloid P component) and C-reactive protein in serum. Clin Exp Immunol 1978 ; 32 : 119-24.
106. Woo P, O'Brien J, Robson M, Ansel B. A genetic marker for systemic amyloidosis in juvenile arthritis. Lancet 1987 ; ii : 767-9.
107. Hawkins PN, Tennent GA, Woo P, Pepys MB. Studies in vivo and in vitro of serum amyloid P component in normals and in a patient with AA amyloidosis. Clin Exp Immunol 1991 ; 84 : 308-16.
108. 2+-binding region of human serum amyloid P component and other pentraxins. Protein Sci 1992 ; 1 : 700-9.
109. Dyck RF, Lockwood M, Kershaw M, Mc Hugh N, Duance VC, Baltz ML, et al. Amyloid P-component is a constitutent of normal human glomerular basement membrane. J Exp Med 1980 ; 152 : 1162-74.
110. Breathnach SM, Melrose SM, Bhogal B, de Beer FC, Dyck RF, Tennent G, et al. Amyloid P-component is located on elastic fibre microfibrils of normal human tissues. Nature 1981 ; 293 : 652-4.
111. Hind CRK, Collins PM, Caspi D, Baltz ML, Pepys MB. Specific chemical dissociation of fibrillar and non-fibrillar components of amyloid deposits. Lancet 1984 ; ii : 376-8.
112. Saïle R, Kandoussi A, Deveaux M, Descamps J, Hachulla E, Cachera C. Quantification of serum amyloid P by enzyme-linked immunosorbent assay. Clin Chem 1991 ; 37; 1742-5.
113. Hawkins PN, Wootton R, Pepys MB. Metabolic studies of radioiodinated serum amyloid P component in normal subjects and patients with systemic amyloidosis. J Clin Invest 1990 ; 86 : 1862-9.
114. Skinner M, Vaitukaitis JL, Cohen AS, Benson MD. Serum amyloid P-component levels in amyloidosis, connective tissue diseases, infections and malignancy as compared to normal serum. J Lab Clin Med 1979 ; 97 : 633-8.
115. Nelson SR, Tennent GA, Sethi D, Gomer PE, Ballardie FW, Amataykul-Chantler S, et al. Serum amyloid P component in chronic renal failure and dialysis. Clin Chim Acta 1991 ; 200 : 191-200.
116. Hawkins PN, Rossor MN, Gallimore JR, Miller B, Moore EG, Pepys MB. Concentration of serum amyloid P component in the CSF as a possible marker of cerebral amyloid deposits in Alzheimer's disease. Biochem Biophys Res Commun 1994 ; 201 : 722-6.
117. Saïle R, Deveaux M, Hachulla E, Descamps J, Duquesnoy B, Marchandise X. Iodine 123-labelled serum amyloid P component scintigraphy in amyloidosis. Eur J Nucl Med 1993 ; 20 : 130-7.